ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

Xavier Montalban; Ralf Gold; Alan J Thompson; Susana Otero-Romero; Maria Pia Amato; Dhia Chandraratna; Michel Clanet; Giancarlo Comi; Tobias Derfuss; Franz Fazekas; Hans Peter Hartung; Eva Havrdova; Bernhard Hemmer; Ludwig Kappos; Roland Liblau; Catherine Lubetzki; Elena Marcus; David H Miller; Tomas Olsson; Steve Pilling; Krysztof Selmaj; Axel Siva; Per Soelberg Sorensen; Maria Pia Sormani; Christoph Thalheim; Heinz Wiendl; Frauke Zipp

doi:10.1177/1352458517751049

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

Xavier Montalban, Ralf Gold, Alan J Thompson, Susana Otero-Romero, Maria Pia Amato, Dhia Chandraratna, Michel Clanet, Giancarlo Comi, Tobias Derfuss, Franz Fazekas, Hans Peter Hartung, Eva Havrdova, Bernhard Hemmer, Ludwig Kappos, Roland Liblau, Catherine Lubetzki, Elena Marcus, David H Miller, Tomas Olsson, Steve PillingKrysztof Selmaj, Axel Siva, Per Soelberg Sorensen, Maria Pia Sormani, Christoph Thalheim, Heinz Wiendl, Frauke Zipp

Department of Clinical Medicine

213 Citations (Scopus)

Abstract

BACKGROUND: Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions.

OBJECTIVES: To develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS.

METHODS: This guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients-Intervention-Comparator-Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique.

RESULTS: A total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus.

CONCLUSION: The present guideline will enable homogeneity of treatment decisions across Europe.

Original language	English
Journal	Multiple Sclerosis Journal
Volume	24
Issue number	2
Pages (from-to)	96-120
ISSN	1352-4585
DOIs	https://doi.org/10.1177/1352458517751049
Publication status	Published - 1 Feb 2018

Access to Document

10.1177/1352458517751049

1352458517751049Final published version, 151 KB

Cite this

Montalban, X., Gold, R., Thompson, A. J., Otero-Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comi, G., Derfuss, T., Fazekas, F., Hartung, H. P., Havrdova, E., Hemmer, B., Kappos, L., Liblau, R., Lubetzki, C., Marcus, E., Miller, D. H., Olsson, T., ... Zipp, F. (2018). ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal, 24(2), 96-120. https://doi.org/10.1177/1352458517751049

Montalban, X, Gold, R, Thompson, AJ, Otero-Romero, S, Amato, MP, Chandraratna, D, Clanet, M, Comi, G, Derfuss, T, Fazekas, F, Hartung, HP, Havrdova, E, Hemmer, B, Kappos, L, Liblau, R, Lubetzki, C, Marcus, E, Miller, DH, Olsson, T, Pilling, S, Selmaj, K, Siva, A, Sorensen, PS, Sormani, MP, Thalheim, C, Wiendl, H & Zipp, F 2018, 'ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis', Multiple Sclerosis Journal, vol. 24, no. 2, pp. 96-120. https://doi.org/10.1177/1352458517751049

@article{17d35812dddd4a41bc4f0c0861f2474e,

title = "ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis",

abstract = "BACKGROUND: Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions.OBJECTIVES: To develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS.METHODS: This guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients-Intervention-Comparator-Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique.RESULTS: A total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus.CONCLUSION: The present guideline will enable homogeneity of treatment decisions across Europe.",

author = "Xavier Montalban and Ralf Gold and Thompson, {Alan J} and Susana Otero-Romero and Amato, {Maria Pia} and Dhia Chandraratna and Michel Clanet and Giancarlo Comi and Tobias Derfuss and Franz Fazekas and Hartung, {Hans Peter} and Eva Havrdova and Bernhard Hemmer and Ludwig Kappos and Roland Liblau and Catherine Lubetzki and Elena Marcus and Miller, {David H} and Tomas Olsson and Steve Pilling and Krysztof Selmaj and Axel Siva and Sorensen, {Per Soelberg} and Sormani, {Maria Pia} and Christoph Thalheim and Heinz Wiendl and Frauke Zipp",

year = "2018",

month = feb,

day = "1",

doi = "10.1177/1352458517751049",

language = "English",

volume = "24",

pages = "96--120",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications",

number = "2",

}

TY - JOUR

T1 - ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

AU - Montalban, Xavier

AU - Gold, Ralf

AU - Thompson, Alan J

AU - Otero-Romero, Susana

AU - Amato, Maria Pia

AU - Chandraratna, Dhia

AU - Clanet, Michel

AU - Comi, Giancarlo

AU - Derfuss, Tobias

AU - Fazekas, Franz

AU - Hartung, Hans Peter

AU - Havrdova, Eva

AU - Hemmer, Bernhard

AU - Kappos, Ludwig

AU - Liblau, Roland

AU - Lubetzki, Catherine

AU - Marcus, Elena

AU - Miller, David H

AU - Olsson, Tomas

AU - Pilling, Steve

AU - Selmaj, Krysztof

AU - Siva, Axel

AU - Sorensen, Per Soelberg

AU - Sormani, Maria Pia

AU - Thalheim, Christoph

AU - Wiendl, Heinz

AU - Zipp, Frauke

PY - 2018/2/1

Y1 - 2018/2/1

N2 - BACKGROUND: Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions.OBJECTIVES: To develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS.METHODS: This guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients-Intervention-Comparator-Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique.RESULTS: A total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus.CONCLUSION: The present guideline will enable homogeneity of treatment decisions across Europe.

AB - BACKGROUND: Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions.OBJECTIVES: To develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS.METHODS: This guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients-Intervention-Comparator-Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique.RESULTS: A total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus.CONCLUSION: The present guideline will enable homogeneity of treatment decisions across Europe.

U2 - 10.1177/1352458517751049

DO - 10.1177/1352458517751049

M3 - Journal article

C2 - 29353550

SN - 1352-4585

VL - 24

SP - 96

EP - 120

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 2

ER -

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

Abstract

Access to Document

Fingerprint

Cite this